PharmaCyte Biotech, Inc. Announces Completion of Master Cell Bank
January 10, 2018 at 07:50 pm IST
Share
PharmaCyte Biotech, Inc. announced that the Master Cell Bank (MCB) of cells that will be used in its upcoming trial in patients with locally advanced non-metastatic and inoperable pancreatic cancer has been fully populated. This work was done for PharmaCyte by Eurofins Lancaster Laboratories in Lancaster, Pennsylvania. As previously announced, rather than now expanding the MCB into a Working Cell Bank (WCB) which would then supply vials of cells for encapsulation by Austrianova using the Cell-in-a-Box® technology as part of PharmaCyte’s pancreatic cancer therapy, the company has decided to use vials of cells from the MCB for this purpose. This decision was made because the MCB contains far more vials of cells than needed for use in the planned clinical trial and will accelerate PharmaCyte’s clinical development timeline. Now that population of the MCB has been completed, cells from the MCB must undergo a variety of tests to satisfy regulatory requirements. The first set of tests will be conducted by Eurofins. Once satisfactory test results are received, the vials of cells will be shipped to Austrianova for encapsulation and further testing. Using vials from the MCB will save a significant amount of time required by Austrianova to generate the data required by the FDA to be included in PharmaCyte’s Investigational New Drug (IND) Application.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
PHARMACYTE BIOTECH, INC. 
